Outcomes of preoperative chemotherapy for colorectal cancer with peritoneal metastasis underwent cytoreductive surgery
Clinical and Translational Oncology · 2023
DOI: 10.1007/s12094-023-03250-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2023. Verfasst von Binying Peng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Peritoneal Neoplasms, Colorectal Neoplasms, Hyperthermia, Induced, Intestinal Obstruction. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: The Sixth Affiliated Hospital of Sun Yat-Sen University Clinical Research- "1010" Program, Guangdong Provincial Clinical Research Center for Digestive Diseases, The Sixth Affiliated Hospital of Sun Yat-Sen University Clinical Research- “1010” Program.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: This study aims to assess and compare the extent to which preoperative chemotherapy prior to CRS improves survival in patients diagnosed with CRCPM. METHODS: We included 251 patients from 2012 to 2019 in our center. Inverse probability of treatment weighting (IPTW) analysis was used to minimize the selection bias. Survival analysis was performed to compare the survival outcomes. Multivariate Cox regression analysis was conducted to identify prognostic factors. RESULT: The baseline characteristics were well balanced using IPTW (standardized mean difference < 0.1). Preoperative chemotherapy cannot significantly improve overall survival (HR, 1.03; 95% CI 0.71-1.49; P = 0.88). In subgroup analysis, we found that intestinal obstruction after preoperative chemotherapy significantly reduced survival (HR, 2.25; 95% CI 1.01-5.03; P = 0.048), while in the upfront surgery group, intestinal obstruction had no impact on prognosis. CONCLUSION: For CRCPM patients treated with CRS, preoperative chemotherapy does not seem to prolong overall survival. Furthermore, the emergence of intestinal obstruction after chemotherapy may compromise the effectiveness of treatment, resulting in a worse prognosis. This finding has important clinical implications for treatment decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
- Department of General Surgery, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510655, China.
- Department of Anesthesiology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510655, China. wangyli26@mail.sysu.edu.cn.
- Department of General Surgery, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510655, China. luor33@mail2.sysu.edu.cn.
Förderung
- The Sixth Affiliated Hospital of Sun Yat-Sen University Clinical Research- "1010" Program
- Guangdong Provincial Clinical Research Center for Digestive Diseases
- The Sixth Affiliated Hospital of Sun Yat-Sen University Clinical Research- “1010” Program
Zitieren
APA
Peng, B., Liu, Z., Huang, B., Zhang, Y., Su, Y., Wang, H., Wang, Y., & Luo, R. (2023). Outcomes of preoperative chemotherapy for colorectal cancer with peritoneal metastasis underwent cytoreductive surgery. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-023-03250-1
Vancouver
Peng B, Liu Z, Huang B, Zhang Y, Su Y, Wang H, et al. Outcomes of preoperative chemotherapy for colorectal cancer with peritoneal metastasis underwent cytoreductive surgery. Clinical and Translational Oncology. 2023. doi:10.1007/s12094-023-03250-1
BibTeX
@article{Peng2023,
author = {Peng, Binying and Liu, Zhiying and Huang, Binjie and Zhang, Yuanxin and Su, Yiwen and Wang, Hui and Wang, Yanli and Luo, Rui},
title = {Outcomes of preoperative chemotherapy for colorectal cancer with peritoneal metastasis underwent cytoreductive surgery},
journal = {Clinical and Translational Oncology},
year = {2023},
doi = {10.1007/s12094-023-03250-1}
}
EUVIMED